Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Elizabeth Colglazier"'
Autor:
Emily Morell, Elizabeth Colglazier, Jasmine Becerra, Leah Stevens, Martina A. Steurer, Anshuman Sharma, Hung Nguyen, Irfan S. Kathiriya, Stephen Weston, David Teitel, Roberta Keller, Elena K. Amin, Hythem Nawaytou, Jeffrey R. Fineman
Publikováno v:
Pulmonary Circulation, Vol 14, Iss 2, Pp n/a-n/a (2024)
Abstract Cardiac catheterization remains the gold standard for the diagnosis and management of pediatric pulmonary hypertension (PH). There is lack of consensus regarding optimal anesthetic and airway regimen. This retrospective study describes the a
Externí odkaz:
https://doaj.org/article/d29abfe687d84f25b35c00ab08767704
Autor:
Elizabeth Colglazier, Angelica J. Ng, Claire Parker, David Woolsey, Raymond Holmes, Allison Dsouza, Jasmine Becerra, Leah Stevens, Hythem Nawaytou, Roberta L. Keller, Jeffrey R. Fineman
Publikováno v:
Pulmonary Circulation, Vol 13, Iss 3, Pp n/a-n/a (2023)
Abstract Inhaled iloprost (iILO) has shown efficacy in treating patients with hypoxic lung disease and pulmonary hypertension, inducing selective pulmonary vasodilation and improvement in oxygenation. However, its short elimination half‐life of 20
Externí odkaz:
https://doaj.org/article/2d88513449a147b6bdb92cfea3cc7d48
Autor:
Julia McSweeney, Elizabeth Colglazier, Jasmine Becerra, Brienne Leary, Kathleen Miller‐Reed, Stephen Walker, Katy Tillman, Melissa Magness, Michelle Ogawa, Whitney Bannon, Tisha Kivett, Emma O. Jackson, Anne Davis, Cathy Shepard, Susan Richards, Elise Whalen, Shannon Engstrand, Zachary DiPasquale, Jean A. Connor
Publikováno v:
Pulmonary Circulation, Vol 13, Iss 2, Pp n/a-n/a (2023)
Abstract Continuous subcutaneous (SubQ) treprostinil is an effective therapy for pediatric patients diagnosed with pulmonary hypertension (PH). To date, the clinical characteristics and factors associated with failure to tolerate this therapy have no
Externí odkaz:
https://doaj.org/article/d2fc43a93d194f25a4bff2c0c00d1da7
Autor:
Elizabeth Colglazier, Leah Stevens, Claire Parker, Hythem M. Nawaytou, Elena K. Amin, Jasmine Becerra, Martina Steurer, Jeffrey R. Fineman
Publikováno v:
Pulmonary Circulation, Vol 12, Iss 4, Pp n/a-n/a (2022)
Abstract Despite the increase in therapeutic options, parenteral prostacyclins remain the cornerstone in the medical management of pulmonary arterial hypertension (PAH). While the use of parenteral prostacyclins in pediatric patients is well document
Externí odkaz:
https://doaj.org/article/03616419f5be40c295373339b3656d14
Autor:
Rachel Farrell, Elizabeth Colglazier, Claire Parker, Leah Stevens, Eric D. Austin, Jeffrey R. Fineman
Publikováno v:
Pulmonary Circulation, Vol 12, Iss 3, Pp n/a-n/a (2022)
Abstract There has been a growing interest in the role that genetic factors influence pediatric pulmonary vascular disease. In fact, data suggests that genetic factors contribute to ~42% of pediatric‐onset pulmonary hypertension. Although animal an
Externí odkaz:
https://doaj.org/article/520bd271afb24e2bb740437a66c7bfab
Autor:
Stephanie M. Tsoi, Kirk Jones, Elizabeth Colglazier, Claire Parker, Hythem Nawaytou, David Teitel, Jeffrey R. Fineman, Roberta L. Keller
Publikováno v:
Pulmonary Circulation, Vol 12, Iss 3, Pp n/a-n/a (2022)
Abstract We present a case of a late preterm infant placed on extracorporeal life support in the first day of life for persistent pulmonary hypertension of the newborn. Developmental arrest, pulmonary vascular hypertensive changes, and pulmonary inte
Externí odkaz:
https://doaj.org/article/3fac05cae6894bd78dead81451f4a2f2
Autor:
Leah Stevens, Elizabeth Colglazier, Claire Parker, Elena K. Amin, Hythem Nawaytou, David Teitel, Vadiyala M. Reddy, Carrie L. Welch, Wendy K. Chung, Jeffrey R. Fineman
Publikováno v:
Pulmonary Circulation, Vol 12, Iss 1, Pp n/a-n/a (2022)
Abstract Despite therapeutic advances over the past decades, pulmonary arterial hypertension (PAH) and related pulmonary vascular diseases continue to cause significant morbidity and mortality in neonates, infants, and children. Unfortunately, an ade
Externí odkaz:
https://doaj.org/article/f67346e3c86b4204a9da642a3dcac58f
Autor:
Lawrence M. Nogee, Emily Griffin, Samo Vesel, William Christopher Golden, Laura Southgate, Yoel Hirsch, Wendy K. Chung, John D. Coulson, Matthias Haimel, Michael A Harris, Josef Ekstein, Rajiv D. Machado, Julie Hoover-Fong, Elizabeth Colglazier, Stefan Gräf, Lewis H. Romer, Carrie L. Welch, Nicholas W. Morrell, Jeffrey R. Fineman, Charaka Hadinnapola, Maruša Debeljak, Marta Bleda
Publikováno v:
Journal of Medical Genetics. 59:906-911
BackgroundThe molecular genetic basis of pulmonary arterial hypertension (PAH) is heterogeneous, with at least 26 genes displaying putative evidence for disease causality. Heterozygous variants in the ATP13A3 gene were recently identified as a new ca
Publikováno v:
J Pediatr Pharmacol Ther
There is limited published experience with transitioning pediatric patients from parenteral treprostinil to oral selexipag therapy. In addition, published transitions have typically been protracted, taking several weeks to complete. We present a case
Autor:
Rebecca Johnson Kameny, Elizabeth Colglazier, Hythem Nawaytou, Phillip Moore, V. Mohan Reddy, David Teitel, Jeffrey R. Fineman
Publikováno v:
Pulmonary Circulation, Vol 7 (2017)
Pulmonary arterial hypertension (PAH) is a frequent complication of congenital heart disease as a consequence of altered pulmonary hemodynamics with increased pulmonary blood flow and pressure. The development of pulmonary vascular disease (PVD) in t
Externí odkaz:
https://doaj.org/article/08eb1f499e364f6c98341035a95cca2b